Cowen and Company’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Cowen and Company’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-11,600	Closed	-$65K	–	543
2020 Q2	$65K	Buy	+11,600	New	+$896K	0.01%	267
2020 Q1	–	Sell	-34,900	Closed	-$3K	–	556
2019 Q4	$3K	Buy	+34,900	New	+$3.12M	﹤0.01%	426

Other funds holding ICPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Cowen and Company's ICPT Position: Q4 2022 in Review

Cowen and Company sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2022, closing a stake of 57,300 shares — an estimated $13K sold.

Cowen and Company first reported a position in ICPT in Q4 2019 and held it in 2 quarters. The position peaked at $732K in Q4 2019. 144 funds tracked by Wall St. Rank hold ICPT as of Q4 2022.

Cowen and Company reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
Cowen and Company sold 57,300 Intercept Pharmaceuticals, Inc. shares in Q4 2022, an estimated $13K.
Cowen and Company first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2019 and held it in 2 quarters.
Cowen and Company's Intercept Pharmaceuticals, Inc. position peaked at $732K in Q4 2019.
144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2022.

Based on Cowen and Company's 13F filing for Q4 2022, filed 9 Feb 2023.